GAP vs LEVI

GAP exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9, indicating solid operational improvement despite a lack of Altman Z-Score data. However, the stock is currently trading at a premium to both its Graham Number ($22.13) and Intrinsic Value ($14.91), suggesting limited valuation upside. While the balance sheet is stable and the P/E ratio is low relative to the sector, significant headwinds include negative earnings growth (-16% YoY) and a starkly bearish insider sentiment. The disconnect between analyst 'Buy' ratings and the 0/100 technical trend suggests a high-risk environment for new entries.

LEVI presents a compelling growth-at-a-reasonable-price (GARP) opportunity, anchored by a stable Piotroski F-Score of 4/9 and a current price ($22.30) that sits comfortably below its growth-based intrinsic value of $40.12. While the Graham Number suggests a lower defensive floor of $13.25, the company's exceptional ROE of 25.41% and strong earnings growth (32.6% YoY) justify a premium. Despite bearish insider sentiment and a weak technical trend, the fundamental trajectory is supported by consistent earnings beats and a P/E ratio significantly lower than the sector average.